Project UpdateMay 27, 2026, 08:47 AM
Traws Pharma advances broad-spectrum antiviral for Hantavirus, Ebola
AI Summary
Traws Pharma, Inc. announced the advancement of a novel proprietary broad-spectrum combination anti-viral agent. This investigational therapy utilizes a unique "dual-strike" mechanism to combat critical global viral threats like Hantavirus, Ebola, and Lassa. The company is concurrently scaling up manufacturing and engaging with health agencies, including the CDC, NAFDAC, and AMA, to fast-track clinical development, ensure emergency supply, and establish local manufacturing in Nigeria for global access.
Key Highlights
- Traws Pharma advances a novel proprietary broad-spectrum combination anti-viral agent.
- The investigational combination uses a unique "dual-strike" mechanism of action.
- It targets Hantavirus, Ebola, and Lassa, with potential for low pill burden.
- Both components have been safely evaluated in human studies as single agents.
- Non-clinical development and evaluation in validated animal models are underway in BSL-3/BSL-4 labs.
- Company is scaling up chemical development and manufacturing for immediate supply and stockpiling.
- Interactions planned with CDC, NAFDAC, and AMA to fast-track clinical development and global access.
- Strategic alignment aims for sustainable, local manufacturing in Nigeria.
Price Impact
More from TRAW